These findings establish SV2B as a novel diagnostic biomarker for TFE3‐RCC and validate SV2B‐NF‐κB signaling as a therapeutic target, providing potential strategies for managing TFE3‐RCC. This evidence concerns the gene NFKB1 and renal cell carcinoma.